Shares of Gland Pharma declined 3% to their day's low of Rs 2,827 on the BSE on Friday after 1.22 crore shares changed hands in two separate block deals worth Rs 2,941 crore and Rs 2,877 crore. According to various reports, Fosun Pharma Industrial was looking to divest a 5% stake in the company through a block deal. As of June 30, 2026, Fosun Pharma Industrial held 8,53,93,894 shares, representing a 51.77% stake in Gland Pharma, according to BSE data.
The block deal has been launched with a floor price of Rs 2,763 per share, representing a discount of up to 5% to Gland Pharma’s current market price. The offer size is pegged at Rs 2,279.5 crore. A lock-up will apply to any further sale of shares for up to 12 months, per multiple media reports.
Separately, Gland Pharma had informed the exchanges on September 1 that the United States Food and Drug Administration (USFDA) had conducted a routine Good Manufacturing Practice (GMP) inspection at its VSEZ Sterile Oncology Formulations Facility and API Facility in Visakhapatnam between August 24, 2026 and September 1, 2026. The inspection concluded with ZERO (0) Form 483 Observations.
Gland Pharma Q1 results
The company reported a consolidated net profit of Rs 317 crore for Q1FY27 on August 10, marking a 47% year-on-year increase from Rs 216 crore in the corresponding quarter last year. Revenue from operations rose 20% year-on-year to Rs 1,800 crore from Rs 1,506 crore in Q1FY26.
Gland Pharma’s quarterly R&D investment stood at Rs 77.2 crore in Q1FY27, while adjusted EBITDA increased 37% year-on-year. The adjusted EBITDA margin was 28%. Its CDMO business contributed 50% of total revenue and grew 20% year-on-year during the quarter, while the B2B business accounted for the remaining 50% and recorded 19% year-on-year growth.
Year-to-date, the pharma stock has gained 69.96%. The company had a market capitalisation of Rs 47,920.34 crore on the BSE as of September 3, 2026.
Established in Hyderabad in 1978, Gland Pharma has expanded from a contract manufacturer of small-volume liquid parenteral products into one of the largest and fastest-growing generic injectable manufacturing companies. It has a presence across 60 countries, including the United States, Europe, Canada, Australia, India and other markets.
The company primarily follows a business-to-business (B2B) model and has a track record in pharmaceutical research and development, manufacturing and marketing complex injectables.
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times.)
